Citrus Heights, CA, United States of America

Paul Flynn

USPTO Granted Patents = 7 

Average Co-Inventor Count = 5.9

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
7 patents (USPTO):Explore Patents

Title: Paul Flynn: Innovator in Cancer Treatment

Introduction

Paul Flynn is a notable inventor based in Citrus Heights, CA (US). He has made significant contributions to the field of oncology through his innovative work on CDK9 inhibitors. With a total of 7 patents, Flynn's research focuses on developing new agents for the treatment of cancer.

Latest Patents

Flynn's latest patents include groundbreaking work on CDK9 inhibitors and polymorphs thereof. These patents describe a crystalline form and/or polymorph of a compound that has the potential to be used as agents for cancer treatment. The patents detail methods associated with the preparation and use of these polymorphs, as well as pharmaceutical compositions that incorporate them. Additionally, they provide methods for preparing a compound with a specific formula, including its salt, tautomer, or zwitterionic forms.

Career Highlights

Throughout his career, Paul Flynn has worked with prominent companies in the pharmaceutical industry. He has been associated with Sumitomo Pharma Oncology, Inc. and Sumitomo Dainippon Pharma Oncology, Inc., where he has contributed to the development of innovative cancer therapies. His work has been instrumental in advancing the understanding and treatment of cancer.

Collaborations

Flynn has collaborated with talented individuals in his field, including Adam Siddiqui-Jain and Yuka Arikawa. These collaborations have further enhanced his research and development efforts in oncology.

Conclusion

Paul Flynn's contributions to cancer treatment through his innovative patents and collaborations highlight his dedication to improving patient outcomes. His work continues to influence the field of oncology and represents a significant advancement in cancer therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…